Deep dives on aging reversal technologies. What the research actually shows.
From $50-a-month telehealth scripts to six-figure concierge programs and frontier therapies priced like luxury cars. What each tier actually buys you — and where the markup hides.
Read →The relationship between what an intervention costs and how well it's proven is almost perfectly backwards. The cheapest things have the best data. The most expensive have the least.
Read →Quietly extended lifespan in the NIA's testing program and racked up cardiovascular and kidney wins in humans. One of the most underrated interventions in the field.
Read →The most consistent animal longevity data of any compound. But the gap between mouse models and human evidence is wider than most longevity clinics will tell you.
Read →Originally for diabetes. Then weight loss. Now the anti-inflammatory and neuroprotective data is piling up. This might be the biggest longevity story of 2025-2026.
Read →Standard reference ranges are population averages, not longevity benchmarks. The difference between "normal" and "optimal" is where the actionable data lives.
Read →